Effect of occult metastases on survival in node-negative breast cancer.
BACKGROUND
Retrospective and observational analyses suggest that occult lymph-node metastases are an important prognostic factor for disease recurrence or survival among patients with breast cancer. Prospective data on clinical outcomes from randomized trials according to sentinel-node involvement have been lacking.


METHODS
We randomly assigned women with breast cancer to sentinel-lymph-node biopsy plus axillary dissection or sentinel-lymph-node biopsy alone. Paraffin-embedded tissue blocks of sentinel lymph nodes obtained from patients with pathologically negative sentinel lymph nodes were centrally evaluated for occult metastases deeper in the blocks. Both routine staining and immunohistochemical staining for cytokeratin were used at two widely spaced additional tissue levels. Treating physicians were unaware of the findings, which were not used for clinical treatment decisions. The initial evaluation at participating sites was designed to detect all macrometastases larger than 2 mm in the greatest dimension.


RESULTS
Occult metastases were detected in 15.9% (95% confidence interval [CI], 14.7 to 17.1) of 3887 patients. Log-rank tests indicated a significant difference between patients in whom occult metastases were detected and those in whom no occult metastases were detected with respect to overall survival (P=0.03), disease-free survival (P=0.02), and distant-disease-free interval (P=0.04). The corresponding adjusted hazard ratios for death, any outcome event, and distant disease were 1.40 (95% CI, 1.05 to 1.86), 1.31 (95% CI, 1.07 to 1.60), and 1.30 (95% CI, 1.02 to 1.66), respectively. Five-year Kaplan-Meier estimates of overall survival among patients in whom occult metastases were detected and those without detectable metastases were 94.6% and 95.8%, respectively.


CONCLUSIONS
Occult metastases were an independent prognostic variable in patients with sentinel nodes that were negative on initial examination; however, the magnitude of the difference in outcome at 5 years was small (1.2 percentage points). These data do not indicate a clinical benefit of additional evaluation, including immunohistochemical analysis, of initially negative sentinel nodes in patients with breast cancer. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00003830.).
University of Vermont College of Medicine and Vermont Cancer Center, Department of Pathology, Burlington, VT 05405-0068, USA. donald.weaver@vtmednet.org
Donald L
DL
Weaver
Takamaru
T
Ashikaga
David N
DN
Krag
Joan M
JM
Skelly
Stewart J
SJ
Anderson
Seth P
SP
Harlow
Thomas B
TB
Julian
Eleftherios P
EP
Mamounas
Norman
N
Wolmark
D001365:Axilla; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D008875:Middle Aged; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy; D017211:Treatment Failure
Cancer. 1989 Jan 1;63(1):181-7
2910416
Mod Pathol. 2010 May;23 Suppl 2:S26-32
20436499
Lancet Oncol. 2007 Oct;8(10):881-8
17851130
Cancer. 1997 Oct 1;80(7):1188-97
9317169
Am J Surg Pathol. 2003 Jun;27(6):842-5
12766591
J Clin Oncol. 2005 Oct 20;23(30):7703-20
16157938
Cancer. 1948 Jul;1(2):238-41
18875036
Am J Surg Pathol. 2009 Nov;33(11):1583-9
19730364
Lancet Oncol. 2010 Oct;11(10):927-33
20863759
J Natl Cancer Inst. 2010 Mar 17;102(6):410-25
20190185
Ann Surg Oncol. 2007 Dec;14(12):3378-84
17899293
J Natl Cancer Inst. 1959 Apr;22(4):719-48
13655060
Cancer. 2000 Mar 1;88(5):1099-107
10699901